REGN654.27+4.73%
REGN · US
1j range: 600.66 → 790.81 · per 2026-07-02
Volgende earnings
2026-07-30
over 23d
Recent materieel nieuws
- Regeneron (REGN) Secures FDA Priority Review And EMA Acceptance For Cemdisiran2026-07-04T16:15
- Regeneron's Applications for gMG Drug Accepted by FDA and EMA2026-06-23T18:24
- REGENXBIO Rises In Premarket As FDA Says No New Studies Needed For NAVSUNLI BLA Resubmission2026-06-22T12:51
- Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)2026-06-22T11:00
- Regeneron Pharmaceuticals Announces That Both The FDA And EMA Have Accepted Regulatory Applications For Cemdisiran To Treat Adult Patients With Generalized Myasthenia Gravis Who Are Anti-Acetylcholine Receptor Antibody-Positive2026-06-22T07:08
- Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program2026-06-17T10:55
- Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities2026-06-08T02:48
Wil je deze diepte op elke stock die je volgt?
Koersvogel schrijft een daily AI digest op 165+ stocks, weekly theses, earnings briefings, en alerts — voor €19/mnd. Gratis tier beschikbaar.
Geen beleggingsadvies. Koersvogel is een research-tool. AI-geschreven content is informationeel, geen koop/verkoop-aanbeveling. Beleggingsbeslissingen zijn jouw verantwoordelijkheid.